Urologic oncology
Journal
Overview
publication venue for
-
Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original investigations volume 35, issue 6, June 2017, pages 356-362.
2022
-
The association between frailty, hypogonadism, and postoperative outcomes among men undergoing radical cystectomy.
2024
-
Long-term outcomes of pelvic-fascia sparing robotic-assisted radical prostatectomy versus standard technique: Superior urinary function and quality of life without compromising oncologic efficacy in a single-surgeon series.
2024
-
Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites.
2023
-
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer.
2023
-
Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma.
2023
-
Conditional survival of stage III non-seminoma testis cancer patients..
41.
2023
-
Insurer coverage of prostate cancer biomarkers.
2023
-
Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer..
41.
2023
-
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder..
41.
2022
-
Collecting duct carcinoma: Epidemiology, clinical characteristics and survival..
41.
2022
-
Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis..
41.
2022
-
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy..
41.
2022
-
Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity..
40.
2022
-
Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma..
40.
2022
-
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer..
40.
2022
-
Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core..
40.
2022
-
A multidisciplinary approach to optimize primary prostate cancer biobanking.
2022
-
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity..
40.
2022
-
Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists..
40.
2022
-
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?
2022
-
Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma.
2022
-
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
2021
-
Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy..
40.
2021
-
Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma.
2021
-
Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy?
2021
-
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma..
39.
2021
-
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis..
39.
2021
-
The effect of race on stage at presentation and survival in upper tract urothelial carcinoma..
39.
2021
-
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02..
40.
2021
-
Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer..
39.
2021
-
Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study..
39.
2021
-
The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients..
39.
2021
-
Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer..
39.
2021
-
Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study..
39.
2021
-
Tumor size and genomic risk in localized prostate cancer..
39.
2021
-
Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study..
39.
2021
-
Diagnostic yield of repeat evaluation for asymptomatic microscopic hematuria after negative initial workup..
39.
2020
-
The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer..
39.
2020
-
Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?.
39.
2020
-
A population-level analysis of nonsquamous penile cancer: The importance of histology..
39.
2020
-
The role of surgical experience in patient selection, surgical quality, and outcomes in robot-assisted radical cystectomy..
39.
2020
-
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab..
39.
2020
-
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy..
39.
2020
-
The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis..
39.
2020
-
Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma..
38.
2020
-
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey..
39.
2020
-
Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort..
38.
2020
-
Primary Ta high grade bladder tumors: Determination of the risk of progression..
39.
2020
-
Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size..
38.
2020
-
Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer..
39.
2020
-
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival..
38.
2020
-
Bladder cancer incidence rates and trends in young adults aged 20-39 years..
38.
2020
-
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer..
38.
2020
-
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer..
39.
2020
-
The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort..
38.
2020
-
The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy..
38.
2020
-
Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions..
38.
2020
-
The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC)..
38.
2020
-
Prognostic value of the SPOP mutant genomic subclass in prostate cancer..
38.
2020
-
Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis..
38.
2020
-
Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma..
38.
2020
-
Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy..
38.
2020
-
Histomorphological analysis of false positive PI-RADS 4 and 5 lesions..
38.
2020
-
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer..
38.
2020
-
Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration..
38.
2020
-
Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients..
38.
2020
-
PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy..
38.
2019
-
Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer..
38.
2019
-
Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?.
38.
2019
-
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy..
38.
2019
-
The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma..
37.
2019
-
Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?.
38.
2019
-
Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma..
37.
2019
-
Definitive and sustained increase in prostate cancer metastases in the United States..
37.
2019
-
Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates..
37.
2019
-
How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder..
37.
2019
-
Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer..
37.
2019
-
A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study)..
37.
2019
-
Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study..
37.
2019
-
Perioperative, oncological and functional outcomes after robotic partial nephrectomy vs. cryoablation in the elderly: A propensity score matched analysis..
37.
2019
-
National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer..
37.
2019
-
Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer..
36.
2019
-
Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer..
37.
2018
-
Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder..
37.
2018
-
Role of serum cholinesterase in patients treated with salvage radical prostatectomy..
37.
2018
-
Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy..
37.
2018
-
Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy..
36.
2018
-
A urinary microRNA (miR) signature for diagnosis of bladder cancer..
36.
2018
-
Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in the electronic health record..
36.
2018
-
Robotic versus open partial nephrectomy for highly complex renal masses: Comparison of perioperative, functional, and oncological outcomes..
36.
2018
-
Effect of blood transfusions on oncological outcomes of surgically treated localized renal cell carcinoma..
36.
2018
-
Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma..
36.
2018
-
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance..
36.
2018
-
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer..
36.
2018
-
Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy..
36.
2018
-
Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool..
36.
2018
-
Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer..
36.
2018
-
Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer..
36.
2017
-
Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification..
36.
2017
-
Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C..
36.
2017
-
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations..
37.
2017
-
Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)..
36.
2017
-
Concordance between patient-reported and physician-reported sexual function after radical prostatectomy..
36.
2017
-
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes..
36.
2017
-
Predictors of genitourinary malignancy in patients with asymptomatic microscopic hematuria..
36.
2017
-
Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer..
36.
2017
-
Population-based study of the incidence and survival for intraductal carcinoma of the prostate..
35.
2017
-
The effect of AB0 and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma..
35.
2017
-
Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy..
35.
2017
-
Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis..
35.
2017
-
Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?.
35.
2017
-
Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database..
35.
2017
-
Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study..
35.
2017
-
Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study..
35.
2017
-
Regionalization of radical cystectomy in the United States..
35.
2017
-
Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer..
35.
2017
-
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy..
35.
2017
-
Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma..
35.
2017
-
Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer..
35.
2017
-
Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer..
35.
2017
-
Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy..
35.
2017
-
Health status and use of partial nephrectomy in older adults with early-stage kidney cancer..
35.
2016
-
Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma..
35.
2016
-
The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes..
35.
2016
-
Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer..
35.
2016
-
External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study..
35.
2016
-
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer..
34.
2016
-
Technique and outcomes of bladder neck intussusception during robot-assisted laparoscopic prostatectomy: A parallel comparative trial..
34.
2016
-
Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer..
34.
2016
-
The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer..
34.
2016
-
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer..
34.
2016
-
Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?.
35.
2016
-
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer..
34.
2016
-
Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer..
34.
2016
-
The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models..
35.
2016
-
Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer..
34.
2016
-
Accuracy of urethral frozen section during radical cystectomy for bladder cancer..
34.
2016
-
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis..
34.
2016
-
Determinants of radical cystectomy operative time..
34.
2016
-
Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?.
34.
2016
-
GATA3 immunohistochemical expression in invasive urothelial carcinoma..
34.
2016
-
Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy..
34.
2016
-
Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution..
34.
2016
-
The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm..
34.
2016
-
Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes..
34.
2015
-
Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial..
34.
2015
-
Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups..
34.
2015
-
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity..
34.
2015
-
Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design..
33.
2015
-
Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study..
33.
2015
-
Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools..
33.
2015
-
Patterns of care for readmission after radical cystectomy in New York State and the effect of care fragmentation..
33.
2015
-
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging..
33.
2015
-
BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study..
33.
2015
-
The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry..
33.
2015
-
Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?.
33.
2014
-
The burden of skeletal-related events in patients with prostate cancer and bone metastasis..
33.
2014
-
Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model..
33.
2014
-
The association between nerve sparing and a positive surgical margin during radical prostatectomy..
33.
2014
-
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)..
32.
2014
-
The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma..
33.
2014
-
Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort..
33.
2014
-
Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer..
32.
2014
-
Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly..
33.
2014
-
Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness..
32.
2014
-
Adherence to surveillance guidelines after radical cystectomy: a population-based analysis..
32.
2014
-
Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy..
32.
2014
-
Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer..
32.
2014
-
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States..
32.
2014
-
The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder..
32.
2014
-
Prognostic effect of serum and tissue YKL-40 levels in bladder cancer..
32.
2014
-
Minimal changes in the systemic immune response after nephrectomy of localized renal masses..
32.
2014
-
Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy..
32.
2014
-
Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder..
32.
2014
-
Local tumor destruction in renal cell carcinoma--an inpatient population-based study..
32.
2014
-
Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature..
32.
2014
-
Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer..
32.
2013
-
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma..
32.
2013
-
High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy..
32.
2013
-
Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?.
32.
2013
-
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance..
32.
2013
-
The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy..
32.
2013
-
Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models..
32.
2013
-
Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death..
32.
2013
-
Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?.
32.
2013
-
Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy..
31.
2012
-
Indications for and anatomical extent of pelvic lymph node dissection for prostate cancer: practice patterns of uro-oncologists in North America..
31.
2012
-
Morbidity and costs of salvage vs. primary radical prostatectomy in older men..
31.
2012
-
Discharge patterns after radical prostatectomy in the United States of America..
31.
2011
-
Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma..
31.
2011
-
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer..
31.
2011
-
Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells..
31.
2011
-
Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy..
31.
2011
-
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer..
31.
2011
-
Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder..
31.
2011
-
RET protein expression in papillary renal cell carcinoma..
30.
2011
-
Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma..
30.
2010
-
The effect of minimally invasive and open radical prostatectomy surgeon volume..
30.
2010
-
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer..
29.
2010
-
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy..
30.
2010
-
Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?.
29.
2010
-
The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy..
29.
2009
-
Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?.
29.
2008
-
Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: results from CaPSURE..
28.
2008
-
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model..
27.
2008
-
A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate..
27.
2008
-
Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder..
25.
2007
-
Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts..
25.
2007
-
Franklin, Lavoisier, and Mesmer: origin of the controlled clinical trial..
23.
2005
-
Medical care cost of patients with prostate cancer..
23.
2005
-
Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors..
21.
2003
-
A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men..
7.
2002
-
Mode of presentation of renal cell carcinoma provides prognostic information..
7.
2002
-
Cytokine therapy in renal cell cancer..
5.
2000
-
Timing of cystectomy for superficial bladder tumors..
5.
2000
-
Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management..
5.
2000
-
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate..
4.
1998
-
Updated concepts and treatment of carcinoma in situ..
4.
1998
-
Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer..
3.
1997
-
Prediction of focal extracapsular extension at radical prostatectomy: Relative merit of transrectal ultrasound, endorectal magnetic resonance imaging, prostate specific antigen, prostate specific antigen density, and systematic biopsy..
2.
1996
-
Selecting clinical research projects for the urologic oncologist..
2.
1996
-
Uncertainty and outcome of invasive bladder tumors..
2.
1996
-
Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder..
1.
1995
-
Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4)..
33.
2015
-
Segmental ureterectomy for upper tract urothelial carcinoma: two procedures with different indications..
31.
2013
-
The new era of precision urobiome: RE: "Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study" by Chipollini et al.
2020
-
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy..
33.
2015
-
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval..
33.
2015
-
Training of a surgeon-scientist..
27.
2009
-
A medical oncologist's perspective on the treatment of patients with genitourinary malignancies..
27.
2009
-
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer.
2021
-
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer.
2021
-
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges.
2021
-
Systemic therapy in bladder preservation.
2020
-
Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis.
2020
-
Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis.
2019
-
Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature.
2019
-
Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis.
2019
-
Introduction to "Molecular drivers of prostate cancer development, progression, and resistance to therapy".
2018
-
Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
2018
-
A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer.
2018
-
Novel biomarkers in bladder cancer.
2018
-
A multidisciplinary approach for the management of earlier stage renal cell carcinoma.
2018
-
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.
2016
-
Prostate cancer risk stratification with magnetic resonance imaging.
2016
-
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
2016
-
Immunotherapy for genitourinary malignancies in the here and now!
2015
-
Pediatric and adolescent renal cell carcinoma.
2015
-
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
2015
-
Salvage high-dose chemotherapy for germ cell tumors.
2015
-
Enzalutamide: Development from bench to bedside.
2015
-
Biomarkers for immunotherapy in genitourinary malignancies.
2015
-
Biomarker development in the context of urologic cancers.
2015
-
Reprint of: The prostate cancer genome: Perspectives and potential.
2015
-
Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.
2015
-
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
2014
-
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.
2014
-
Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice.
2014
-
Prostate cancer biomarkers: an update.
2014
-
Highlights from the first symposium on upper tract urothelial carcinoma.
2014
-
Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy.
2013
-
The prostate cancer genome: perspectives and potential.
2013
-
Urine markers for detection and surveillance of bladder cancer.
2013
-
Current status of focal primary therapy for prostate cancer.
2012
-
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.
2012
-
Salvage therapies after radiation therapy.
2012
-
Prostate-specific membrane antigen-based imaging.
2012
-
Environmental toxicology of testicular cancer.
2012
-
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.
2012
-
Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
2012
-
Radical prostatectomy: positive surgical margins matter.
2012
-
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.
2010
-
Statistical consideration for clinical biomarker research in bladder cancer.
2010
-
Bladder cancer in the elderly.
2009
-
Do high-volume hospitals and surgeons provide better care in urologic oncology?
2009
-
Optimal timing of radical cystectomy for patients with T1 bladder cancer.
2009
-
Optimizing outcomes at every stage of bladder cancer: do we practice it?
2009
-
Laparoscopic radical prostatectomy: contemporary comparison with open surgery.
2007
-
Low risk prostate cancer in men under age 65: the case for definitive treatment.
2007
-
The use and abuse of data: nomograms and talking to patients about clinical medicine.
2007
-
A new era in the treatment of urothelial carcinoma.
2023
-
Antibody-drug conjugates for urothelial carcinoma.
2023
-
The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
2023
-
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
2023
-
Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy.
2022
-
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
2022
-
Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
2022
-
Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis.
2022
-
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis.
2022
-
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints.
2021
-
Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
2021
-
Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.
2021
-
Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review.
2021
-
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?
2021
-
Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma.
2021
-
The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis.
2020
-
Role of lymph node dissection in renal cell cancer.
2019
-
Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer.
2008
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)